94 related articles for article (PubMed ID: 24074237)
1. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.
Zell M; Husser C; Kuhlmann O; Schwab D; Uchimura T; Kemei T; Kawashima K; Yamane M; Pähler A
Xenobiotica; 2014 Apr; 44(4):369-78. PubMed ID: 24074237
[TBL] [Abstract][Full Text] [Related]
2. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
3. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers.
Chen LZ; Jungnik A; Mao Y; Philip E; Sharp D; Unseld A; Seman L; Woerle HJ; Macha S
Xenobiotica; 2015; 45(6):520-9. PubMed ID: 25547626
[TBL] [Abstract][Full Text] [Related]
4. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
[TBL] [Abstract][Full Text] [Related]
5. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.
Yamane M; Kawashima K; Yamaguchi K; Nagao S; Sato M; Suzuki M; Honda K; Hagita H; Kuhlmann O; Poirier A; Fowler S; Funk C; Simon S; Aso Y; Ikeda S; Ishigai M
Xenobiotica; 2015 Mar; 45(3):230-8. PubMed ID: 25350082
[TBL] [Abstract][Full Text] [Related]
6. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B
Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.
Kasahara-Ito N; Fukase H; Ogama Y; Saito T; Ohba Y; Shimada S; Takano Y; Ichihara T; Terao K; Nakamichi N; Kumagai Y; Ikeda S
Drug Res (Stuttg); 2017 Jun; 67(6):349-357. PubMed ID: 28427104
[TBL] [Abstract][Full Text] [Related]
8. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Ohtake Y; Sato T; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Yamaguchi M; Takami K; Yeu SY; Ahn KH; Matsuoka H; Morikawa K; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
J Med Chem; 2012 Sep; 55(17):7828-40. PubMed ID: 22889351
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
10. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
11. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor.
Yamada H; Ohira H; Ikegami F; Nakamura K; Takahashi A; Abe K; Inano A; Shimada S; Miyata K; Saito T; Ohba Y; Terao K; Ohnishi A
Drug Res (Stuttg); 2020 Sep; 70(9):401-409. PubMed ID: 32707593
[TBL] [Abstract][Full Text] [Related]
12. Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation.
Ishibashi Y; Matsui T; Yamagishi S
Horm Metab Res; 2016 Mar; 48(3):191-5. PubMed ID: 26158396
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
14. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
16. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
Hussey EK; Clark RV; Amin DM; Kipnes MS; O'Connor-Semmes RL; O'Driscoll EC; Leong J; Murray SC; Dobbins RL; Layko D; Nunez DJ
J Clin Pharmacol; 2010 Jun; 50(6):623-35. PubMed ID: 20056803
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
18. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
19. [New fixed combination in type 2 diabetes].
Red
MMW Fortschr Med; 2016 Apr; 158(7):74. PubMed ID: 27071602
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
Macha S; Lang B; Pinnetti S; Broedl UC
Int J Clin Pharmacol Ther; 2014 Nov; 52(11):973-80. PubMed ID: 25161155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]